Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
Peginterferon alfa-2b Action Pathway
Homo sapiens
Drug Action Pathway
Peginterferon alfa-2b, also known as Pegintron or Sylatron, is a purified recombinant human interferon. It is used as part of combination therapy to treat chronic Hepatitis C caused by the Hepatitis C Virus (HCV). It is also used as an adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection. The mechanism of action is the inhibition of the viral replication in infected cells caused by the binding of the peginterferon to the human type 1 interferon receptors causing them to dimerize. This, in consequence, activates the JAK-STATS pathway which increases the expression of multiple genes involved in the innate antiviral response. Its immunomodulatory effects are the enhancement of the phagocytic activity, the activation of NK cells, the stimulation of cytotoxic T-lymphocytes, and the upregulation of the Th1 T-helper cell subset.
References
Peginterferon alfa-2b Pathway References
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M: DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037.
Pubmed: 29126136
Myers RP, Shah H, Burak KW, Cooper C, Feld JJ: An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol. 2015 Jan-Feb;29(1):19-34. doi: 10.1155/2015/692408. Epub 2015 Jan 13.
Pubmed: 25585348
Bagaglio S, Uberti-Foppa C, Morsica G: Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use. Drugs. 2017 Jul;77(10):1043-1055. doi: 10.1007/s40265-017-0753-x.
Pubmed: 28497432
Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27. doi: 10.1021/bc049780h.
Pubmed: 15898717
Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S, Kuwano M, Kojiro M: Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 2006 Oct;26(8):964-75. doi: 10.1111/j.1478-3231.2006.01321.x.
Pubmed: 16953837
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. doi: 10.1093/nar/30.1.412.
Pubmed: 11752352
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
Downloads
Settings